Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.63 |
| ▸ | LTA4H | P09960 | 2/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ESRRG | P62508 | 2/20 | 0.53 |
| ▸ | ESRRB | O95718 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9773251 | 0.98 | HRH3 (0.61) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL6784753 | 0.90 | KDM4E (0.69) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL91406 | 0.81 | HRH3 (0.66) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL14922323 | 0.81 | HRH3 (0.66) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL13305508 | 0.81 | THRA (0.53) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL28144525 | 0.80 | HRH3 (0.70) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL1129242 | 0.80 | EBP (0.62) | HRH3LTA4H | |
| SCHEMBL6557649 | 0.79 | MAOB (0.57) | LTA4HKDM4EALDH1A1LMNA | |
| SCHEMBL23875573 | 0.79 | MAPT (0.60) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL14922719 | 0.79 | HRH3 (0.63) | HRH3LTA4HKEAP1NFE2L2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385093-B2 | Estrogen receptor imaging agents | NORTHEASTERN UNIVERSITY (US) | 2019-08-20 | — | — | US | claimed |
| US-20150344518-A1 | ESTROGEN RECEPTOR IMAGING AGENTS | UNITED STATES DEPARTMENT OF ENERGY | 2015-12-03 | — | — | US | claimed |
| WO-2014093378-A1 | ESTROGEN RECEPTOR IMAGING AGENTS | NORTHEASTERN UNIVERSITY (US) | 2014-06-19 | — | — | WO | claimed |
| WO-2025128616-A1 | COMPOUNDS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250136568-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| EP-4444714-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | Nanjing Zenshine Pharmaceuticals Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| CN-118742545-A | Fused heterocyclic compounds as PI3K alpha inhibitors | 南京征祥医药有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240199621-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2024-06-20 | — | — | US | disclosed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| EP-0110434-A1 | Steroid intermediates substituted at position 11, and process for their preparation | ROUSSEL-UCLAF (FR) | 1984-06-13 | — | — | EP | disclosed |
| US-4447424-A | ANTIFERTILITY, ANTIINFLAMMATORY AGENT, HORMONE INHIBITOR | ROUSSEL UCLAF (FR) | 1984-05-08 | — | — | US | disclosed |
| US-4386085-A | ANTIGLUCOCORTICOIDS | ROUSSELL UCLAF (FR) | 1983-05-31 | — | — | US | disclosed |
| US-4383998-A | Furo-(3,4-c)-pyridine derivatives and their pharmaceutical use | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 1983-05-17 | — | — | US | disclosed |
| EP-0078158-A2 | Novel alkane and alkene derivatives and their preparation and use | Farmos Group Ltd. (FI) | 1983-05-04 | — | — | EP | disclosed |
| EP-0057115-A2 | Steroid derivatives substituted in the 11-beta position, process for their preparation, their utilization as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1982-08-04 | — | — | EP | disclosed |
| EP-0002097-B1 | TRIPHENYLALKENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-08-05 | — | — | EP | disclosed |
| US-4206234-A | Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-06-03 | — | — | US | disclosed |
| EP-0002097-A1 | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385093-B2 | Estrogen receptor imaging agents | ESR1, GPER1, ESR2 | HRH3 2318/4885LTA4H 1774/4885KEAP1 1952/4885 |
| US-20250136568-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | HRH3 4376/4885LTA4H 2056/4885KEAP1 4094/4885 |
| US-11795169-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K2, MAP4K5 | HRH3 3307/4885LTA4H 3063/4885KEAP1 567/4885 |
| US-20240199621-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K2, MAP4K5 | HRH3 3307/4885LTA4H 3063/4885KEAP1 567/4885 |
| US-20150344518-A1 | ESTROGEN RECEPTOR IMAGING AGENTS | ESR1, GPER1, ESR2 | HRH3 2318/4885LTA4H 1774/4885KEAP1 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.